Detection of Free Prostate-Specific Antigen Using a Novel Single-Chain Antibody (scAb)-Based Magneto-Immunosensor

被引：15
作者：
Zapatero-Rodríguez J. [1 ,2 ]
Liébana S. [3 ,4 ]
Sharma S. [1 ]
Gilgunn S. [1 ,2 ]
Drago G.A. [3 ]
O’Kennedy R. [1 ,2 ]
机构：
[1] Biomedical Diagnostics Institute (BDI), Dublin City University, Glasnevin
[2] School of Biotechnology, Dublin City University, Glasnevin
[3] Applied Enzyme Technology Ltd., Gwent Group Ltd., Pontypool
[4] Pragmatic Diagnostics S.L., Mòdul de Recerca B- Campus de la UAB, Bellaterra (Cerdanyola del Vallès), 08193, Barcelona
来源：
BioNanoScience | 2018年 / 8卷 / 2期
关键词：
Electrochemical amperometric immunosensor; Magneto-ELISA; Paramagnetic particles; Prostate-specific antigen (PSA); Recombinant scAb antibody;
D O I：
10.1007/s12668-017-0394-2
中图分类号：
学科分类号：
摘要：
The proportion of prostate-specific antigen (PSA) circulating in the free form can help to differentiate prostate cancer from benign prostate disease. In this paper, novel highly specific single-chain antibody (scAb) fragments were conjugated to magnetic particles (MPs) for the recognition and magnetic separation of free PSA (fPSA). A sandwich-type immunoassay method was developed, in which fPSA was captured by the scAb-conjugated MPs and labelled by a secondary antibody, conjugated to horseradish peroxidase (HRP) enzyme. The biosensor was constructed on carbon screen-printed electrodes (SPEs) modified with magnetic particles for increased surface area and fast reaction kinetics, thus enhancing binding capacity. The amperometric response was measured at −0.15 V, using hydrogen peroxide as the HRP substrate and hydroquinone (HQ) as the electrochemical mediator. The magneto-immunosensor demonstrated a sensitivity of 0.5 ng mL−1, with a linear detection range up to 10 ng mL−1 of fPSA. © 2017, Springer Science+Business Media New York.
引用
收藏
页码：680 / 689
页数：9
相关论文
共 33 条
  • [1] Cancer Facts & Figures 2014, (2014)
  • [2] Heidenreich A., Bellmunt J., Bolla M., Joniau S., Mason M., Matveev V., Mottet N., Chmid H.-P., van der Kwast T., Wiegel T., Zattoni F., EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease, European Urology, 59, 1, pp. 61-71, (2011)
  • [3] Ezenwa E.V., Tijani K.H., Jeje E.A., Soriyan O.O., Ogunjimi M.A., Ojewola R.W., Ojewola O., Ajie I., El-Nahas A.R., The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0–10.0 ng/mL) in Nigeria, Arab Journal of Urology, 10, 4, pp. 394-400, (2012)
  • [4] Moyer V.A., Screening for prostate cancer: US Preventive Services Task Force recommendation statement, Annals of Internal Medicine, 157, 2, pp. 120-134, (2012)
  • [5] Consensus Statements on PSA Testing in Asymptomatic Men in the UK—information for Health Professionals [Online], (2016)
  • [6] American Cancer Society, (2016)
  • [7] Gilgunn S., Conroy P.J., Saldova R., Rudd P.M., O'kennedy R.J., Aberrant PSA glycosylation—a sweet predictor of prostate cancer, Nature Reviews Urology, 10, 2, pp. 99-107, (2013)
  • [8] Healy D.A., Hayes C.J., Leonard P., McKenna L., O'Kennedy R., Biosensor developments: application to prostate-specific antigen detection, Trends in Biotechnology, 25, 3, pp. 125-131, (2007)
  • [9] McPartlin D.A., O'Kennedy R.J., Point-of-care diagnostics, a major opportunity for change in traditional diagnostic approaches: potential and limitations, Expert Review of Molecular Diagnostics, 14, 8, pp. 979-998, (2014)
  • [10] Sharma S., Zapatero-Rodriguez J., O'Kennedy R., Prostate cancer diagnostics: clinical challenges and the ongoing need for disruptive and effective diagnostic tools, Biotechnology Advances, (2016)
1234